vaccinogeninc.com
Vaccinogen Treating Colon Cancer with OncoVAX ImmunotherapyVaccinogen is a biotechnology company that produces personalized vaccines which use a patient's immune system to fight cancer.
http://www.vaccinogeninc.com/
Vaccinogen is a biotechnology company that produces personalized vaccines which use a patient's immune system to fight cancer.
http://www.vaccinogeninc.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Saturday
LOAD TIME
0.1 seconds
16x16
32x32
64x64
128x128
VACCINOGEN INC.
JAY SUN
5300 W●●●●●● DRIVE
SUI●●●406
FRE●●●ICK , MD, 21703
US
View this contact
VACCINOGEN INC.
JAY SUN
5300 W●●●●●● DRIVE
SUI●●●406
FRE●●●ICK , MD, 21703
US
View this contact
VACCINOGEN INC.
JAY SUN
5300 W●●●●●● DRIVE
SUI●●●406
FRE●●●ICK , MD, 21703
US
View this contact
BUY YOUR DOMAIN
16
YEARS
6
MONTHS
16
DAYS
ENOM, INC.
WHOIS : whois.enom.com
REFERRED : http://www.enom.com
PAGES IN
THIS WEBSITE
20
SSL
EXTERNAL LINKS
32
SITE IP
75.126.122.4
LOAD TIME
0.134 sec
SCORE
6.2
Vaccinogen Treating Colon Cancer with OncoVAX Immunotherapy | vaccinogeninc.com Reviews
https://vaccinogeninc.com
Vaccinogen is a biotechnology company that produces personalized vaccines which use a patient's immune system to fight cancer.
vaccinogeninc.com
Jason D. Howard, Vaccinogen Director of Epitope-Based Vaccine Project
http://www.vaccinogeninc.com/vaccinogen/leadership/jason-d-howard-phd
Andrew L. Tussing. Peter Morsing, Ph.D. Michael G. Hanna, Jr., Ph.D. Paul Leonard, Ph.D. Rachel L. Hoover, MSc, MBA. Barry Boyd, M.D., M.S. Earl V. Miller, MBA. Drs Dinand van der Linde, MSc, MA. HC Hoover, Jr., M.D. Andrew L. Tussing. Michael G. Hanna, Jr., Ph.D. Human Monoclonal Antibodies (HuMabs) Program. OncoVax Fact Sheet (PDF). Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 1. Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 2. Manufacturing - Stage 1. Manufacturing - Stage 2.
Peter Morsing, Vaccinogen Global Head of Business Development
http://www.vaccinogeninc.com/vaccinogen/leadership/peter-morsing-phd
Andrew L. Tussing. Peter Morsing, Ph.D. Michael G. Hanna, Jr., Ph.D. Paul Leonard, Ph.D. Rachel L. Hoover, MSc, MBA. Barry Boyd, M.D., M.S. Earl V. Miller, MBA. Drs Dinand van der Linde, MSc, MA. HC Hoover, Jr., M.D. Andrew L. Tussing. Michael G. Hanna, Jr., Ph.D. Human Monoclonal Antibodies (HuMabs) Program. OncoVax Fact Sheet (PDF). Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 1. Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 2. Manufacturing - Stage 1. Manufacturing - Stage 2.
Dr. Herbert C. Hoover, Vaccinogen Senior Medical Advisor
http://www.vaccinogeninc.com/vaccinogen/leadership/hc-hoover-jr-md
Andrew L. Tussing. Peter Morsing, Ph.D. Michael G. Hanna, Jr., Ph.D. Paul Leonard, Ph.D. Rachel L. Hoover, MSc, MBA. Barry Boyd, M.D., M.S. Earl V. Miller, MBA. Drs Dinand van der Linde, MSc, MA. HC Hoover, Jr., M.D. Andrew L. Tussing. Michael G. Hanna, Jr., Ph.D. Human Monoclonal Antibodies (HuMabs) Program. OncoVax Fact Sheet (PDF). Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 1. Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 2. Manufacturing - Stage 1. Manufacturing - Stage 2.
John Powers, Vaccinogen Logistics & Manufacturing Advisor
http://www.vaccinogeninc.com/vaccinogen/leadership/john-powers
Andrew L. Tussing. Peter Morsing, Ph.D. Michael G. Hanna, Jr., Ph.D. Paul Leonard, Ph.D. Rachel L. Hoover, MSc, MBA. Barry Boyd, M.D., M.S. Earl V. Miller, MBA. Drs Dinand van der Linde, MSc, MA. HC Hoover, Jr., M.D. Andrew L. Tussing. Michael G. Hanna, Jr., Ph.D. Human Monoclonal Antibodies (HuMabs) Program. OncoVax Fact Sheet (PDF). Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 1. Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 2. Manufacturing - Stage 1. Manufacturing - Stage 2.
Vaccinogen Board of Directors - Dr. Ben Carson, Andrew Tussing
http://www.vaccinogeninc.com/vaccinogen/board-of-directors
Andrew L. Tussing. Peter Morsing, Ph.D. Michael G. Hanna, Jr., Ph.D. Paul Leonard, Ph.D. Rachel L. Hoover, MSc, MBA. Barry Boyd, M.D., M.S. Earl V. Miller, MBA. Drs Dinand van der Linde, MSc, MA. HC Hoover, Jr., M.D. Andrew L. Tussing. Michael G. Hanna, Jr., Ph.D. Human Monoclonal Antibodies (HuMabs) Program. OncoVax Fact Sheet (PDF). Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 1. Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 2. Manufacturing - Stage 1. Manufacturing - Stage 2.
TOTAL PAGES IN THIS WEBSITE
20
vaccinogeninc.investorroom.com
Investor Welcome - Vaccinogen
http://vaccinogeninc.investorroom.com/index.php
Human Monoclonal Antibodies (HuMabs) Program. OncoVAX For Colon Cancer. Stage III Colon Cancer. Additional Potential OncoVAX applications. Human Monoclonal Antibodies (HuMabs) Program. Vaccinogen is a biotechnology company with more than three decades of research into combating cancer by using the body’s own immune system. It is the producer of OncoVAX, an immunotherapy for Stage II colon cancer. Jun 16, 2016. Vaccinogen Announces Filing of Oncavert Patent Application. Dec 2, 2015. Baltimore, MD 21231.
vaccinogeninc.investorroom.com
Corporate Governance - Vaccinogen
http://vaccinogeninc.investorroom.com/corporate-governance
Human Monoclonal Antibodies (HuMabs) Program. OncoVAX For Colon Cancer. Stage III Colon Cancer. Additional Potential OncoVAX applications. Human Monoclonal Antibodies (HuMabs) Program. The Board of Directors of Vaccinogen, Inc. has established the following document to serve as a guideline for the conduct and operation of the Board and all matters related to proper corporate governance. Corporate Governance Guidelines Vaccinogen 11-25-14.pdf. 949 Fell Street, 2nd Floor. Baltimore, MD 21231.
vaccinogeninc.investorroom.com
Investor Alerts - Vaccinogen
http://vaccinogeninc.investorroom.com/investor-alerts
Human Monoclonal Antibodies (HuMabs) Program. OncoVAX For Colon Cancer. Stage III Colon Cancer. Additional Potential OncoVAX applications. Human Monoclonal Antibodies (HuMabs) Program. Get News Alerts by Email. Get News Alerts by Email. If youre a working journalist that works out of a newsroom location, youll see our news come in over the wire. If you happen to be working from home or are interested in a more direct way of receiving our news releases, we offer you two distinct and automated options.
vaccinogeninc.investorroom.com
Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board - May 5, 2015
http://vaccinogeninc.investorroom.com/2015-05-05-Vaccinogen-Names-Co-Founder-and-CEO-Andrew-L-Tussing-as-Chairman-of-the-Board
Human Monoclonal Antibodies (HuMabs) Program. OncoVAX For Colon Cancer. Stage III Colon Cancer. Additional Potential OncoVAX applications. Human Monoclonal Antibodies (HuMabs) Program. Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board. Benjamin S. Carson, Sr., MD Steps Down from Board of Directors, Chairman Role and Medical Advisory Board to Focus on His Candidacy for the Republican Presidential Nomination. May 5, 2015. May 5, 2015. Via the Republican nomination. Vaccinogen e...
vaccinogeninc.investorroom.com
Financial Information - Vaccinogen Inc.
http://vaccinogeninc.investorroom.com/financial-reporting
Human Monoclonal Antibodies (HuMabs) Program. OncoVAX For Colon Cancer. Stage III Colon Cancer. Additional Potential OncoVAX applications. Human Monoclonal Antibodies (HuMabs) Program. This section of the Vaccinogen Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 949 Fell Street, 2nd Floor. Baltimore, MD 21231. 7825 VM Emmen, Netherlands.
vaccinogeninc.investorroom.com
Investor Welcome - Vaccinogen
http://vaccinogeninc.investorroom.com/welcome
Human Monoclonal Antibodies (HuMabs) Program. OncoVAX For Colon Cancer. Stage III Colon Cancer. Additional Potential OncoVAX applications. Human Monoclonal Antibodies (HuMabs) Program. Vaccinogen is a biotechnology company with more than three decades of research into combating cancer by using the body’s own immune system. It is the producer of OncoVAX, an immunotherapy for Stage II colon cancer. Jun 16, 2016. Vaccinogen Announces Filing of Oncavert Patent Application. Dec 2, 2015. Baltimore, MD 21231.
vaccinogeninc.investorroom.com
Vaccinogen Relocates Corporate Headquarters to Baltimore - Feb 24, 2015
http://vaccinogeninc.investorroom.com/2015-02-24-Vaccinogen-Relocates-Corporate-Headquarters-to-Baltimore
Human Monoclonal Antibodies (HuMabs) Program. OncoVAX For Colon Cancer. Stage III Colon Cancer. Additional Potential OncoVAX applications. Human Monoclonal Antibodies (HuMabs) Program. Vaccinogen Relocates Corporate Headquarters to Baltimore. Move puts company in ideal position to attract top scientific and medical talent to advance OncoVAX clinical trial. Feb 24, 2015. Feb 24, 2015. To a 10,000 square-foot facility at 949 Fell Street in Baltimore, MD. The relocation was completed on February 22. Tranche...
vaccinogeninc.investorroom.com
Stock Information - Vaccinogen
http://vaccinogeninc.investorroom.com/stock-information
Human Monoclonal Antibodies (HuMabs) Program. OncoVAX For Colon Cancer. Stage III Colon Cancer. Additional Potential OncoVAX applications. Human Monoclonal Antibodies (HuMabs) Program. 024 - $0.30. 024 - $2.45. Quote data delayed by at least 15 minutes. 949 Fell Street, 2nd Floor. Baltimore, MD 21231. 7825 VM Emmen, Netherlands. U of Amsterdam Science Park 406. 1098 XH, Amsterdam, Netherlands. For More Information: info@vaccinogeninc.com. For More Information: 410-387-4000.
TOTAL LINKS TO THIS WEBSITE
32
Vaccinogen.net
Vaccinogen.org
Vaccinogen.us
Vaccinogenasia.com
Vaccinogenchina.com
Vaccinogen Treating Colon Cancer with OncoVAX Immunotherapy
Andrew L. Tussing. Michael G. Hanna, Jr., Ph.D. Peter Morsing, Ph.D. Jason D. Howard, Ph.D. Earl V. Miller, MBA. Drs Dinand van der Linde, MSc, MA. HC Hoover, Jr., M.D. Andrew L. Tussing. Michael G. Hanna, Jr., Ph.D. Human Monoclonal Antibodies (HuMabs) Program. OncoVax Fact Sheet (PDF). Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 1. Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 2. Manufacturing - Stage 1. Manufacturing - Stage 2. Manufacturing - Stage 3. Stage III Colon Cancer.
vaccinogeninc.investorroom.com
Investor Welcome - Vaccinogen
Human Monoclonal Antibodies (HuMabs) Program. OncoVAX For Colon Cancer. Stage III Colon Cancer. Additional Potential OncoVAX applications. Human Monoclonal Antibodies (HuMabs) Program. Vaccinogen is a biotechnology company with more than three decades of research into combating cancer by using the body’s own immune system. It is the producer of OncoVAX, an immunotherapy for Stage II colon cancer. May 5, 2015. Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board. Feb 24, 2015.
Vaccinogeninc.net
Vaccinogeninc.org
Edimark TV - L'actualité des spécialités médicales en vidéo
Vous devez vous identifier pour accéder à cette fonction. Mot de passe* :. Rester connecté :. Mot de passe oublié? MOT DE PASSE OUBLIÉ? Infections à Clostridium difficile. Infections à Clostridium difficile. Infections à Clostridium difficile. L'actualité médicale en vidéo. Epidémiologie de la SEP : une révolution! ICD : une pathologie souvent difficile à vivre! Comment annoncer la maladie? Droit européen : un droit supranational. ECCMID 2014 : quelle antibiothérapie prescrire dans les ICD?
Cours international francophone de vaccinologie
Accueil Cours de Vaccinologie. Faute d'un nombre suffisant d'inscrits en 2015, le prochain Cours international francophone de vaccinologie se déroulera à l'École du Val-de-Grâce. La 8è Journée Jean-Gérard Guillet de vaccinologie clinique aura par contre bien lieu le jeudi 2 avril 2015. Le CIFV permet sous certaines conditions l'obtention d'un diplôme universitaire et la validation d'un module du Master professionnel Mention Santé Publique, Spécialité Santé Internationale. Page lue en 0,0090 seconde (7/0).
SOCIAL ENGAGEMENT